» Articles » PMID: 39058183

Consistency of Multi-Month Antiretroviral Therapy Dispensing and Association with Viral Load Coverage Among Pediatric Clients Living with HIV in Mozambique

Overview
Date 2024 Jul 26
PMID 39058183
Authors
Affiliations
Soon will be listed here.
Abstract

With the increase in uptake of multi-month antiretroviral therapy dispensing (MMD) for children, little is known about consistency of MMD receipt over time and its association with virological outcomes. This analysis aims to assess the uptake of 3-month MMD among children, consistent receipt of MMD after uptake, and clinical outcomes following transition to MMD in 16 health facilities in Gaza and Inhambane Provinces. This is a secondary analysis involving children <15 years living with HIV with clinical visits during the period from September 2019 to August 2020. Of 4383 children, 82% ever received MMD (at least one pickup of a 3-month MMD supply) during the study period but only 40% received it consistently (defined as MMD at every visit during the study period). Consistent MMD was most common among older children and children without indications of clinical instability. Overall viral load (VL) coverage was 40% (733/1851). Consistent MMD was significantly associated with lower odds of having a VL (0.78, 95% CI: 0.64-0.95). In conclusion, while receipt of a multi-month supply was common particularly during the early days of the COVID-19 pandemic, only a minority of children received consistent MMD; however, there is a need to ensure children with fewer visits still receive timely VL monitoring.

Citing Articles

Renewing Our Focus on Vulnerable Populations Among People Living with HIV.

Ayieko J, Thorp M, Ghebremichael M Trop Med Infect Dis. 2024; 9(11).

PMID: 39591284 PMC: 11598306. DOI: 10.3390/tropicalmed9110278.

References
1.
Kim M, Wanless R, Caviness A, Golin R, Amzel A, Ahmed S . Multimonth Prescription of Antiretroviral Therapy Among Children and Adolescents: Experiences From the Baylor International Pediatric AIDS Initiative in 6 African Countries. J Acquir Immune Defic Syndr. 2018; 78 Suppl 2:S71-S80. PMC: 6110288. DOI: 10.1097/QAI.0000000000001730. View

2.
Faturiyele I, Appolinare T, Ngorima-Mabhena N, Fatti G, Tshabalala I, Tukei V . Outcomes of community-based differentiated models of multi-month dispensing of antiretroviral medication among stable HIV-infected patients in Lesotho: a cluster randomised non-inferiority trial protocol. BMC Public Health. 2018; 18(1):1069. PMC: 6116392. DOI: 10.1186/s12889-018-5961-0. View

3.
Vella S . Addressing barriers to the end of AIDS by 2030. Lancet HIV. 2015; 2(9):e360-1. DOI: 10.1016/S2352-3018(15)00161-7. View

4.
Gill M, Herrera N, Guilaze R, Mussa A, Dengo N, Nhangave A . Virologic Outcomes and ARV Switch Profiles 2 Years After National Rollout of Dolutegravir to Children Less Than 15 Years in Southern Mozambique. Pediatr Infect Dis J. 2023; 42(10):893-898. DOI: 10.1097/INF.0000000000004037. View

5.
Mugo C, Zubayr B, Ezeokafor N, Oyawola B, Ekele D, Madueke L . Effect of Dolutegravir and Multimonth Dispensing on Viral Suppression Among Children With HIV. J Acquir Immune Defic Syndr. 2023; 93(3):229-236. PMC: 10256312. DOI: 10.1097/QAI.0000000000003190. View